Fig. 4
From: Prognosis prediction based on methionine metabolism genes signature in gliomas
The relationship between the Met metabolism genes signature and clinical characteristics. (A) The landscape of Met metabolism gene signature-related clinic pathological features of gliomas in the TCGA database. (B) The landscape of Met metabolism gene signature‐related clinic pathological features of gliomas in the CGGA database. (C-F) The risk scores were significantly higher in gliomas with grade IV GBM, IDH wild-type, 1p/19q non-codeletion, or MGMT promoter unmethylation in the TCGA databases. (G-J) The risk scores were significantly higher in gliomas with grade IV GBM, IDH wild-type, 1p/19q non-codeletion, or MGMT promoter unmethylation in the CGGA databases; P < 0.0001; C,G:one-way ANOVA and Tukey’s test; D-F, H-J: unpaired t test. IDH, isocitrate dehydrogenase; WHO, world health organization